We are profiling some individual deals but the biotechnology activity in the IPO market right now is overwhelming. Some market observers are calling it a market top in the segment. As we write this 75% of the deals in active marketing are biotechnology or pharma companies.
We've posted up these nine roadshows to the archive and there is a link to each one after the company blurb.
Argos Therapeutics (ARGS) develops personalized immunotherapies for the treatment of cancer and infectious diseases. Argos employs a specialized white blood cell, called a dendritic cell, to activate an . . .